from the sarcoplasmic reticulum (SR). The type-2 ryanodine receptor (RyR2) is the route through which Ca 2C is released from the SR providing the necessary driving force for cellular contraction. In heart failure, RyR2-channels become abnormally active, or 'leaky', and are unable to remain closed during diastole resulting in unwanted irregular contractile and electrical activity. 1 Defective Zn 2C handling has been shown to contribute to the cellular pathology of certain cardiomyopathies which give rise to impaired contractility including heart failure.
2 This is likely a consequence of altered EC coupling as a result of modified RyR2 function. How zinc impacts upon the contractile force and the release of calcium from intracellular stores in heart is not fully understood.
In the recent study by Woodier and coworkers 3 2C . This suggests that RyR2 gating is altered under these conditions whereby RyR2 gates in a Ca 2C -independent manner with Zn 2C the sole activating ligand. These data indicate that channel dysregulation, through aberrant Zn 2C homeostasis, may play a fundamental role in the generation of heart failure and other arrhythmic diseases.
Cardiomyocytes contain a small but measurable pool of free Zn 2C in the cytosol reported to be »100 pM. 4 Since small changes in the Zn 2C level will have a marked effect on RyR2 activity, this becomes highly relevant when we consider that concentrations of Zn 2C have recently been reported to be transiently elevated to »50 nM during Zn 2C -signaling events. and be under control of Zn 2C . This may contribute toward abnormally high RyR2 channel activity which is associated with heart failure and fatal arrhythmias.
The role of Zn 2C as a high affinity activator of RyR2 able to modulate channel function in the absence of Ca 2C represents a paradigm shift in our understanding of how RyR2 is activated during EC coupling. These new data provide a plausible mechanistic explanation linking Zn 2C dyshomeostasis to certain cardiomyopathies characterized by defective contractility and dysregulated Ca 2C -responses (Fig. 1) . However, in order to substantiate a model for integrated Zn 2C -signaling in the heart, a more detailed understanding of the molecular mechanism by which Zn 2C modulates RyR2 function is required and the further impact this has on cardiac function needs to be examined. Determining the origin of Zn 2C fluxes during the cardiac contraction-relaxation cycle in both health and disease states will also be crucial in advancing our understanding of how cellular Zn 2C shapes EC coupling. Understanding Zn 2C signaling in the heart and unveiling new mechanisms involved in regulating intracellular Ca 2C dynamics in cardiac tissue may highlight potential new drug targets in the fight against heart failure and fatal arrhythmias.
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